Role of the kallikrein–kinin system in traumatic brain injury

Frontiers in Cellular Neuroscience

Volumn 8, Issue November, 2014, Pages 1-5

  Albert Weissenberger, Christiane ^a   Mencl, Stine ^a   Hopp, Sarah ^a   Kleinschnitz, Christoph ^a   Sirén, Anna Leena ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Bradykinin; Factor XII; Kallikrein kinin system; Kinin receptor; Traumatic brain injury

Indexed keywords

ACETYLLYSYLBRADYKININ [7 [3 (2 NAPHTHYL) ALANINE] 8 ISOLEUCINE 9 DEARGININE]; ANATIBANT; APROTININ; BLOOD CLOTTING FACTOR 12; BRADYKININ; DELTIBANT; DIPEPTIDYL CARBOXYPEPTIDASE; ICATIBANT; KALLIDIN; KALLIKREIN; KININ DERIVATIVE; KININ RECEPTOR B1; KININ RECEPTOR B2; MESSENGER RNA; UNCLASSIFIED DRUG;

BRAIN EDEMA; DRUG TOLERABILITY; FIBRINOLYSIS; GLASGOW COMA SCALE; HUMAN; INFLAMMATION; KALLIKREIN KININ SYSTEM; NONHUMAN; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; THROMBOSIS; TRAUMATIC BRAIN INJURY; TREATMENT OUTCOME;

EID: 84908641751     PISSN: 16625102     EISSN: None     Source Type: Journal    
DOI: 10.3389/fncel.2014.00345     Document Type: Review

References (45)

1. Albert-Weissenberger, C., and Sirén, A. L. (2010). Experimental traumatic brain injury. Exp. Transl. Stroke Med.2:16. doi: 10.1186/2040-7378-2-16
2. Albert-Weissenberger, C., Stetter, C., Meuth, S. G., Göbel, K., Bader, M., Sirén, A. L., et al. (2012). Blocking of bradykinin receptor B1 protects from focal closed head injury in mice by reducing axonal damage and astroglia activation. J. Cereb. Blood Flow Metab. 32, 1747-1756. doi: 10.1038/jcbfm.2012.62
3. Ariza, M., Matarin, M. D., Junqué, C., Mataró, M., Clemente, I., Moral, P., et al. (2006). Influence of Angiotensin-converting enzyme polymorphism on neuropsychological subacute performance in moderate and severe traumatic brain injury. J. Neuropsychiatry Clin. Neurosci. 18, 39-44. doi: 10.1176/appi.neuropsych.18.1.39
4. Asemota, A. O., George, B. P., Bowman, S. M., Haider, A. H., and Schneider, E. B. (2013). Causes and trends in traumatic brain injury for United States adolescents. J. Neurotrauma 30, 67-75. doi: 10.1089/neu.2012.2605
5. Auer, L. M., Marth, E., Heppner, F., and Holasek, A. (1979). Proteolytic enzyme activity in patienst with severe head injury and the effect of a proteinase inhibitor. Acta Neurochir. (Wien) 49, 207-217. doi: 10.1007/bf01808960
6. Bernstein, K. E., Shen, X. Z., Gonzalez-Villalobos, R. A., Billet, S., Okwan-Duodu, D., Ong, F. S., et al. (2011). Different in vivo functions of the two catalytic domains of angiotensin-converting enzyme (ACE). Curr. Opin. Pharmacol. 11, 105-111. doi: 10.1016/j.coph.2010.11.001
7. Colman, R. W. (1969). Activation of plasminogen by human plasma kallikrein. Biochem. Biophys. Res. Commun. 35, 273-279. doi: 10.1016/0006-291x(69)90278-2
8. Costa-Neto, C. M., Dillenburg-Pilla, P., Heinrich, T. A., Parreiras-e-Silva, L. T., Pereira, M. G., Reis, R. I., et al. (2008). Participation of kallikrein-kinin system in different pathologies. Int. Immunopharmacol. 8, 135-142. doi: 10.1016/j.intimp.2007.08.003
9. Doppenberg, E. M., Choi, S. C., and Bullock, R. (2004). Clinical trials in traumatic brain injury: lessons for the future. J. Neurosurg. Anesthesiol. 16, 87-94. doi: 10.1097/00008506-200401000-00019
10. Faul, M., Xu, L., Wald, M. M., and Coronado, V. G. (2010). Traumatic Brain Injury in the United States: Emergency Department Visits, Hospitalizations and Deaths, 2002-2006. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Injury Prevention and Control.
11. Fleminger, S., Oliver, D. L., Lovestone, S., Rabe-Hesketh, S., and Giora, A. (2003). Head injury as a risk factor for Alzheimer's disease: the evidence 10 years on; a partial replication. J. Neurol. Neurosurg. Psychiatry 74, 857-862. doi: 10.1136/jnnp.74.7.857
12. Geppetti, P. (1993). Sensory neuropeptide release by bradykinin: mechanisms and pathophysiological implications. Regul. Pept. 47, 1-23. doi: 10.1016/0167-0115(93)90268-d
13. Görlach, C., Hortobágyi, T., Hortobágyi, S., Benyó, Z., Relton, J., Whalley, E. T., et al. (2001). Bradykinin B2, but not B1, receptor antagonism has a neuroprotective effect after brain injury. J. Neurotrauma 18, 833-838. doi: 10.1089/089771501316919193
14. Harford-Wright, E., Thornton, E., and Vink, R. (2010). Angiotensin-converting enzyme (ACE) inhibitors exacerbate histological damage and motor deficits after experimental traumatic brain injury. Neurosci. Lett. 481, 26-29. doi: 10.1016/j.neulet.2010.06.044
15. Hellal, F., Pruneau, D., Palmier, B., Faye, P., Croci, N., Plotkine, M., et al. (2003). Detrimental role of bradykinin B2 receptor in a murine model of diffuse brain injury. J. Neurotrauma 20, 841-851. doi: 10.1089/089771503322385773
16. Heydenreich, N., Nolte, M. W., Göb, E., Langhauser, F., Hofmeister, M., Kraft, P., et al. (2012). C1-inhibitor protects from brain ischemia-reperfusion injury by combined antiinflammatory and antithrombotic mechanisms. Stroke 43, 2457-2467. doi: 10.1161/strokeaha.112.660340
17. Ivashkova, Y., Svetnitsky, A., Mayzler, O., Pruneau, D., Benifla, M., Fuxman, Y., et al. (2006). Bradykinin B2 receptor antagonism with LF 18-1505T reduces brain edema and improves neurological outcome after closed head trauma in rats. J. Trauma 61, 879-885. doi: 10.1097/01.ta.0000234722.98537.01
18. Kaplanski, J., Pruneau, D., Asa, I., Artru, A. A., Azez, A., Ivashkova, Y., et al. (2002). LF 16-0687 Ms, a bradykinin B2 receptor antagonist, reduces brain edema and improves long-term neurological function recovery after closed head trauma in rats. J. Neurotrauma 19, 953-964. doi: 10.1089/089771502320317104
19. Kariya, K., Yamauchi, A., and Sasaki, T. (1985). Regional distribution and characterization of kinin in the CNS of the rat. J. Neurochem. 44, 1892-1897. doi: 10.1111/j.1471-4159.1985.tb07185.x
20. Ker, K., and Blackhall, K. (2008). Beta-2 receptor antagonists for acute traumatic brain injury. Cochrane Database Syst. Rev. 23:CD006686. doi: 10.1002/14651858.cd006686.pub2
21. Kizuki, K., Suzuki, T., Sugaya, K., Noguchi, T., and Kudo, M. (1994). Tissue kallikrein in rat and mouse neurons. Braz. J. Med. Biol. Res. 27, 1891-1896.
22. Langhauser, F., Göb, E., Kraft, P., Geis, C., Schmitt, J., Brede, M., et al. (2012). Kininogen deficiency protects from ischemic neurodegeneration in mice by reducing thrombosis, blood-brain barrier damage and inflammation. Blood120, 4082-4092. doi: 10.1182/blood-2012-06-440057
23. Leeb-Lundberg, L. M., Marceau, F., Müller-Esterl, W., Pettibone, D. J., and Zuraw, B. L. (2005). International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol. Rev. 57, 27-77. doi: 10.1124/pr.57.1.2
24. Longhi, L., Perego, C., Ortolano, F., Zanier, E. R., Bianchi, P., Stocchetti, N., et al. (2009). C1-inhibitor attenuates neurobehavioral deficits and reduces contusion volume after controlled cortical impact brain injury in mice. Crit. Care Med. 37, 659-665. doi: 10.1097/ccm.0b013e318195998a
25. Longhi, L., Perego, C., Zanier, E. R., Ortolano, F., Bianchi, P., Stocchetti, N., et al. (2008). Neuroprotective effect of C1-inhibitor following traumatic brain injury in mice. Acta Neurochir. Suppl. 102, 381-384. doi: 10.1007/978-3-211-85578-2_73
26. Ma, V. Y., Chan, L., and Carruthers, K. J. (2014). Incidence, prevalence, costs and impact on disability of common conditions requiring rehabilitation in the United States: stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, osteoarthritis, rheumatoid arthritis, limb loss and back pain. Arch. Phys. Med. Rehabil. 95, 986.e1-995.e1. doi: 10.1016/j.apmr.2013.10.032
27. Maas, A. I., Roozenbeek, B., and Manley, G. T. (2010). Clinical trials in traumatic brain injury: past experience and current developments. Neurotherapeutics 7, 115-126. doi: 10.1016/j.nurt.2009.10.022
28. Marmarou, A., Guy, M., Murphey, L., Roy, F., Layani, L., Combal, J. P., et al. (2005). A single dose, three-arm, placebo-controlled, phase I study of the bradykinin B2 receptor antagonist Anatibant (LF16-0687Ms) in patients with severe traumatic brain injury. J. Neurotrauma 22, 1444-1455. doi: 10.1089/neu.2005.22.1444
29. Marmarou, A., Nichols, J., Burgess, J., Newell, D., Troha, J., Burnham, D., et al. (1999). Effects of the bradykinin antagonist Bradycor (deltibant, CP-1027) in severe traumatic brain injury: results of a multi-center, randomized, placebo-controlled trial. American Brain Injury Consortium Study Group. J. Neurotrauma 16, 431-444. doi: 10.1089/neu.1999.16.431
30. Narotam, P. K., Rodell, T. C., Nadvi, S. S., Bhoola, K. D., Troha, J. M., Parbhoosingh, R., et al. (1998). Traumatic brain contusions: a clinical role for the kinin antagonist CP-0127. Acta Neurochir. (Wien) 140, 793-802; discussion 802-803. doi: 10.1007/s007010050181
31. Ongali, B., Campos, M. M., Bregola, G., Rodi, D., Regoli, D., Thibault, G., et al. (2003). Autoradiographic analysis of rat brain kinin B1 and B2 receptors: normal distribution and alterations induced by epilepsy. J. Comp. Neurol. 461, 506-519. doi: 10.1002/cne.10706
32. Ongali, B., Hellal, F., Rodi, D., Plotkine, M., Marchand-Verrecchia, C., Pruneau, D., et al. (2006). Autoradiographic analysis of mouse brain kinin B1 and B2 receptors after closed head trauma and ability of Anatibant mesylate to cross the blood-brain barrier. J. Neurotrauma 23, 696-707. doi: 10.1089/neu.2006.23.696
33. Plesnila, N., Schulz, J., Stoffel, M., Eriskat, J., Pruneau, D., and Baethmann, A. (2001). Role of bradykinin B2 receptors in the formation of vasogenic brain edema in rats. J. Neurotrauma 18, 1049-1058. doi: 10.1089/08977150152693746
34. Pruneau, D., Chorny, I., Benkovitz, V., Artru, A., Roitblat, L., and Shapira, Y. (1999). Effect of LF 16-0687MS, a new nonpeptide bradykinin B2 receptor antagonist, in a rat model of closed head trauma. J. Neurotrauma 16, 1057-1065. doi: 10.1089/neu.1999.16.1057
35. Raslan, F., Schwarz, T., Meuth, S. G., Austinat, M., Bader, M., Renné, T., et al. (2010). Inhibition of bradykinin receptor B1 protects mice from focal brain injury by reducing blood-brain barrier leakage and inflammation. J. Cereb. Blood Flow Metab. 30, 1477-1486. doi: 10.1038/jcbfm.2010.28
36. Renné, T., Schmaier, A. H., Nickel, K. F., Blombäck, M., and Maas, C. (2012). In vivo roles of factor XII. Blood 120, 4296-4303. doi: 10.1182/blood-2012-07-292094
37. Revak, S. D., Cochrane, C. G., Bouma, B. N., and Griffin, J. H. (1978). Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma. J. Exp. Med. 147, 719-729. doi: 10.1084/jem.147.3.719
38. Revenko, A. S., Gao, D., Crosby, J. R., Bhattacharjee, G., Zhao, C., May, C., et al. (2011). Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Blood118, 5302-5311. doi: 10.1182/blood-2011-05-355248
39. Schulz, J., Plesnila, N., Eriskat, J., Stoffel, M., Pruneau, D., and Baethmann, A. (2000). LF16-0687 a novel non-peptide bradykinin B2 receptor antagonist reduces vasogenic brain edema from a focal lesion in rats. Acta Neurochir. Suppl. 76, 137-139. doi: 10.1007/978-3-7091-6346-7_28
40. Shakur, H., Andrews, P., Asser, T., Balica, L., Boeriu, C., Quintero, J. D., et al. (2009). The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury. Trials 10:109. doi: 10.1186/1745-6215-10-109
41. Singer, M., and Jones, A. M. (2011). Bench-to-bedside review: the role of C1-esterase inhibitor in sepsis and other critical illnesses. Crit. Care 15:203. doi: 10.1186/cc9304
42. Stover, J. F., Dohse, N. K., and Unterberg, A. W. (2000). Bradykinin 2 receptor antagonist LF 16-0687Ms reduces posttraumatic brain edema. Acta Neurochir. Suppl. 76, 171-175. doi: 10.1007/978-3-7091-6346-7_34
43. Trabold, R., Erös, C., Zweckberger, K., Relton, J., Beck, H., Nussberger, J., et al. (2010). The role of bradykinin B(1) and B(2) receptors for secondary brain damage after traumatic brain injury in mice. J. Cereb. Blood Flow Metab.30, 130-139. doi: 10.1038/jcbfm.2009.196
44. Unterberg, A., Dautermann, C., Baethmann, A., and Müller-Esterl, W. (1986). The kallikrein-kinin system as mediator in vasogenic brain edema. Part 3: Inhibition of the kallikrein-kinin system in traumatic brain swelling. J. Neurosurg. 64, 269-276. doi: 10.3171/jns.1986.64.2.0269
45. Zweckberger, K., and Plesnila, N. (2009). Anatibant, a selective non-peptide bradykinin B2 receptor antagonist, reduces intracranial hypertension and histopathological damage after experimental traumatic brain injury.Neurosci. Lett. 454, 115-117. doi: 10.1016/j.neulet.2009.02.014